Related Experiment Video
Updated: Dec 31, 2025
05:26
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
9.6K
Secondary adherence to beta-blockers after ST-elevation myocardial infarction without ventricular dysfunction.
Ana Padilla López1, Manuel Alós-Almiñana2, José E Peris3
1Servicio de Farmacia de Área, Departamento de Salud de Gandía, Gandía, Valencia, España.
Medicina Clinica
|January 15, 2020
Summary
Secondary adherence to beta-blockers significantly improves 1-year cardiovascular outcomes in patients after a heart attack (STEMI) with preserved heart function. This highlights the importance of consistent medication use for better patient prognosis.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Adequate medication intake is crucial for effective treatment outcomes.
- Beta-blockers are a key therapy following myocardial infarction.
- Understanding adherence impact on cardiovascular events is vital.
Purpose of the Study:
- To determine the effect of beta-blocker prescription and adherence on cardiovascular outcomes.
- To analyze medium- and long-term results after a first ST-elevation myocardial infarction (STEMI).
- To assess outcomes in patients without heart failure and preserved ejection fraction.
Main Methods:
- Retrospective observational study of 460 patients admitted between 2008-2013.
- Analysis of beta-blocker prescription and secondary adherence (proportion of days covered).
- Competing risk analysis for cardiovascular mortality and new vascular events.
Main Results:
- Beta-blocker prescription was not significantly linked to improved outcomes at 1 year.
- Secondary adherence to beta-blockers significantly reduced cardiovascular mortality at 1 year (0.6% vs. 6.6%).
- Adherent patients showed better outcomes compared to non-adherent or non-prescribed groups at 1 year, but not long-term.
Conclusions:
- Secondary adherence to beta-blockers significantly improves the 1-year prognosis after STEMI in patients with preserved left ventricular function.
- Consistent medication use is critical for short-term recovery and outcomes post-myocardial infarction.
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
697
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
697
01:14Myocarditis III: Medical Management
129
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
129
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
1.3K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.3K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.1K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.1K
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.4K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.4K
01:28Acute Coronary Syndrome IV: Interprofessional Care
177
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
177